Oral topotecan: bioavailability and effect of food co-administration.

Autor: Herben, V M M, Rosing, H, Huinink, W W ten Bokkel, Zomeren, D M van, Batchelor, D, Doyle, E, Beusenberg, F D, Beijnen, J H, Schellens, J H M

Publikováno v: British Journal of Cancer. 7/1/99, Vol. 80 Issue 9, p1380. 7p.

Isolation and structural confirmation of N-desmethyl topotecan, a metabolite of topotecan.

Autor: Rosing, H., Herben, V. M. M., Zomeren, D. M. Gortel-van, Hop, E., den Bosch, J. J. Kettenes-van, Huinink, W. W. Bokkel, Beijnen, J. H., Herben, V M, van Gortel-van Zomeren, D M, Kettenes-van den Bosch, J J, ten Bokkel Huinink, W W

Publikováno v: Cancer Chemotherapy & Pharmacology; Feb1997, Vol. 39 Issue 6, p498-504, 7p

Phase I and pharmacokinetic study of the combination of topotecan and ifosfamide administered intravenously every 3 weeks.

Autor: Kerbusch T; Department of Pharmacy and Pharmacology, The Netherlands Cancer Institute/Slotervaart Hospital, Amsterdam, The Netherlands. thomas_kerbusch@sandwich.pfizer.com, Groenewegen G, Mathôt RA, Herben VM, ten Bokkel Huinink WW, Swart M, Ambaum B, Rosing H, Jansen S, Voest EE, Beijnen JH, Schellens JH

Publikováno v: British journal of cancer [Br J Cancer] 2004 Jun 14; Vol. 90 (12), pp. 2268-77.